Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MDM2 | Q00987 | 1/20 | 0.33 |
| ▸ | MAOB | P27338 | 2/20 | 0.32 |
| ▸ | MAOA | P21397 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6353675 | 1.00 | MDM2 (0.33) | MDM2MAOBMAOAALDH1A1MAPT | |
| SCHEMBL6354674 | 0.79 | MDM2 (0.40) | MDM2MAOBMAOAALDH1A1MAPT | |
| SCHEMBL6354675 | 0.79 | MDM2 (0.40) | MDM2MAOBMAOAALDH1A1MAPT | |
| SCHEMBL6353249 | 0.74 | PTPN7 (0.42) | MAOBMAOAALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL6353252 | 0.74 | PTPN7 (0.42) | MAOBMAOAALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL1250660 | 0.73 | FLT3 (0.50) | ALDH1A1 | |
| SCHEMBL1250665 | 0.73 | FLT3 (0.50) | ALDH1A1 | |
| SCHEMBL6355225 | 0.73 | ALDH1A1 (0.41) | MDM2MAOBMAOAALDH1A1MAPT | |
| SCHEMBL6355223 | 0.73 | ALDH1A1 (0.41) | MDM2MAOBMAOAALDH1A1MAPT | |
| Hydrochloric Acid SCHEMBL6353019 | 0.71 | SLC6A2 (0.46) | MAOBMAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050090498-A1 | 3-Quinolin-2(1h)-ylideneindolin-2-one derivative | YAMANOUCHI PHARMACEUTICAL CO., LTD. (JP) | 2005-04-28 | — | — | US | disclosed |
| EP-1396490-A1 | 3-QUINOLINE-2-(1H)-YLIDENEINDOLIN-2-ONE DERIVATIVES | YAMANOUCHI PHARMACEUTICAL CO. LTD. (JP) | 2004-03-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050090498-A1 | 3-Quinolin-2(1h)-ylideneindolin-2-one derivative | KDR, FLT4, FLT1 | MDM2 801/4885MAOB 4555/4885MAOA 4445/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.